Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan in Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06637423Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2024
- Primary completion
- Mar 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in non-muscle-invasive bladder cancer (NMIBC), sponsored by Merck & Co. Primary endpoints: Dose Limiting Toxicity at 7 weeks, Adverse Event at 10 weeks and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06637423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637423.